{"id":"tafenoquine-prophylaxis","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolysis in G6PD-deficient patients"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Tafenoquine acts as a blood schizonticide and hypnozoiticide, meaning it eliminates both the erythrocytic (blood) stage and the dormant liver stage (hypnozoites) of Plasmodium parasites. As an 8-aminoquinoline, it generates reactive oxygen species that damage parasite mitochondrial function, leading to parasite death. This dual activity makes it effective for both treatment and prophylaxis of malaria, particularly P. vivax and P. ovale.","oneSentence":"Tafenoquine is an 8-aminoquinoline that kills malaria parasites by generating reactive oxygen species in the parasite mitochondria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:11:04.757Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Malaria prophylaxis in travelers to endemic regions"},{"name":"Treatment of acute malaria (P. vivax and P. ovale)"}]},"trialDetails":[{"nctId":"NCT06575647","phase":"PHASE4","title":"Vivax Elimination With Tafenoquine (VET) Study","status":"COMPLETED","sponsor":"Shoklo Malaria Research Unit","startDate":"2025-02-19","conditions":"Malaria, Malaria, Vivax, Plasmodium Vivax","enrollment":1242},{"nctId":"NCT06666491","phase":"PHASE3","title":"An Interventional Study to Compare the Efficacy and Safety of Tafenoquine (TQ) and Primaquine (PQ) When Either Are Taken Together With Chloroquine (CQ) for the Treatment of P. Vivax Malaria in Indian Participants Aged 2 Years and Older","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":"Malaria, Vivax","enrollment":300},{"nctId":"NCT05203744","phase":"PHASE4","title":"Escalating Monthly Doses of Tafenoquine in Healthy Volunteers","status":"UNKNOWN","sponsor":"Naval Medical Research Center","startDate":"2022-05-10","conditions":"Prophylaxis","enrollment":200},{"nctId":"NCT01376167","phase":"PHASE2","title":"Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-04-24","conditions":"Malaria, Vivax","enrollment":851}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":67,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TQ"],"phase":"marketed","status":"active","brandName":"Tafenoquine prophylaxis","genericName":"Tafenoquine prophylaxis","companyName":"Naval Medical Research Center","companyId":"naval-medical-research-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tafenoquine is a small molecule used for the prophylaxis of malaria caused by Plasmodium vivax. The exact mechanism of action of tafenoquine is currently unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}